as 06-17-2025 4:00pm EST
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Founded: | 2018 | Country: | United States |
Employees: | N/A | City: | DALLAS |
Market Cap: | 230.1M | IPO Year: | 2021 |
Target Price: | $119.00 | AVG Volume (30 days): | 518.4K |
Analyst Decision: | Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -11.97 | EPS Growth: | N/A |
52 Week Low/High: | $9.62 - $92.00 | Next Earning Date: | 08-12-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
TIL Breaking Stock News: Dive into TIL Ticker-Specific Updates for Smart Investing
Zacks
a day ago
GlobeNewswire
6 days ago
Zacks
13 days ago
GlobeNewswire
15 days ago
GlobeNewswire
18 days ago
Zacks
19 days ago
Zacks
19 days ago
GlobeNewswire
25 days ago
The information presented on this page, "TIL Instil Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.